Management of Lymphocytosis

Initial Assessment and Diagnosis

The management of lymphocytosis depends entirely on the underlying cause and clinical context, with elevated lymphocyte counts alone not warranting treatment in chronic lymphocytic leukemia (CLL), but potentially indicating disease progression in other contexts 1, 2
Identifying whether lymphocytosis represents malignant lymphoproliferation, reactive/benign lymphocytosis, drug-induced lymphocytosis, or hemophagocytic lymphohistiocytosis (HLH) is crucial, with drug-induced lymphocytosis from BTK or PI3K inhibitors being expected and not prompting treatment discontinuation 1, 2, 4
Absolute lymphocyte count and trend over time, lymphocyte morphology, presence of lymphadenopathy, hepatosplenomegaly, or constitutional symptoms, and cytopenias are key diagnostic features to assess, with a progressive increase >50% over 2 months or lymphocyte doubling time <6 months suggesting active disease in CLL 3, 6

The absolute lymphocyte count alone should never be used as the sole indicator for initiating treatment in CLL, with treatment typically only needed if WBC >200-300 × 10⁹/L AND symptomatic leukostasis present 3, 7
Asymptomatic early-stage disease (Rai 0, Binet A) should be monitored without therapy even with elevated counts, while leukostasis is extremely rare in CLL, even with WBC >150,000/μL 3, 7, 8
Treatment is indicated when lymphocytosis occurs WITH at least one of the following: progressive marrow failure, massive or progressive/symptomatic splenomegaly, massive or progressive/symptomatic lymphadenopathy, progressive lymphocytosis, or constitutional symptoms 3, 8
For del(17p) or TP53 mutations, ibrutinib is preferred first-line, while for patients without del(17p)/TP53 mutations, treatment selection should consider age, comorbidities, and IGHV mutation status 1, 7, 8

Lymphocytosis from ibrutinib or idelalisib represents redistribution of lymphocytes from lymph nodes to peripheral blood and does NOT indicate disease progression, with treatment typically continued 1, 2, 4
Transient lymphocytosis occurs in most patients within the first few weeks of ibrutinib/idelalisib treatment, and may persist for several weeks to >12 months, but does not predict early relapse 1, 4
Clinical consequence (leukostasis) is extremely rare, and response category "PR with lymphocytosis" applies when lymph nodes/spleen decrease but lymphocytosis persists 2, 4

HLH represents severe hyperactivation of lymphocytes and macrophages requiring prompt immunosuppressive treatment due to high mortality if untreated, with diagnostic criteria including rapidly rising ferritin >5,000 ng/mL, grade ≥3 organ dysfunction, hemophagocytosis on bone marrow examination, and additional features such as elevated triglycerides, low fibrinogen, or elevated soluble CD25 5, 6
First-line treatment includes anti-IL-6 therapy (tocilizumab) plus aggressive corticosteroids, with second-line treatment including corticosteroids plus anakinra, and last resort treatment including etoposide, which should be avoided if possible due to T-cell toxicity 5

Do not initiate CLL treatment based solely on elevated WBC count without other criteria for active disease, and do not discontinue ibrutinib/idelalisib due to lymphocytosis alone, as this represents expected pharmacologic effect, not treatment failure 1, 2, 3, 4, 7, 8
Do not assume all lymphocytosis in adults is CLL, and do not overlook HLH in patients with lymphocytosis plus fever and cytopenias, as delayed treatment increases mortality 5, 6